Aldeyra Therapeutics, Inc. (ALDX) stock
ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.69+0.02 (+3.63%)
Close on Nov 17, 2026Market cap $41.86MP/E –Yield –
Aldeyra Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Aldeyra Therapeutics's total assets was $47.54M at Jun 30, 2026. For fiscal 2025 it was $72.06M, down 31.1% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $233.14M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.06M | -31.1% |
| FY2024 | Dec 31, 2024 | $104.61M | -29.5% |
| FY2023 | Dec 31, 2023 | $148.33M | -18.2% |
| FY2022 | Dec 31, 2022 | $181.29M | -22.2% |
| FY2021 | Dec 31, 2021 | $233.14M | +179.7% |
| FY2020 | Dec 31, 2020 | $83.35M | +10.4% |
| FY2019 | Dec 31, 2019 | $75.52M | -20.6% |
| FY2018 | Dec 31, 2018 | $95.09M | +115.3% |
| FY2017 | Dec 31, 2017 | $44.17M | +75.4% |
| FY2016 | Dec 31, 2016 | $25.19M | -10.7% |
| FY2015 | Dec 31, 2015 | $28.20M | +221.0% |
| FY2014 | Dec 31, 2014 | $8.79M | +134.7% |
| FY2013 | Dec 31, 2013 | $3.74M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $47.54M | -44.0% |
| Q1 FY2026 | Mar 31, 2026 | $66.48M | -28.7% |
| Q4 FY2025 | Dec 31, 2025 | $72.06M | -31.1% |
| Q3 FY2025 | Sep 30, 2025 | $77.80M | -33.7% |
| Q2 FY2025 | Jun 30, 2025 | $84.96M | -32.6% |
| Q1 FY2025 | Mar 31, 2025 | $93.20M | -34.0% |
| Q4 FY2024 | Dec 31, 2024 | $104.61M | -29.5% |
| Q3 FY2024 | Sep 30, 2024 | $117.32M | -20.3% |
| Q2 FY2024 | Jun 30, 2024 | $126.04M | -19.0% |
| Q1 FY2024 | Mar 31, 2024 | $141.30M | -16.0% |
| Q4 FY2023 | Dec 31, 2023 | $148.33M | -18.2% |
| Q3 FY2023 | Sep 30, 2023 | $147.28M | -22.4% |
| Q2 FY2023 | Jun 30, 2023 | $155.62M | -22.6% |
| Q1 FY2023 | Mar 31, 2023 | $168.22M | -24.5% |
| Q4 FY2022 | Dec 31, 2022 | $181.29M | -22.2% |
| Q3 FY2022 | Sep 30, 2022 | $189.69M | -23.3% |
| Q2 FY2022 | Jun 30, 2022 | $201.02M | -21.6% |
| Q1 FY2022 | Mar 31, 2022 | $222.69M | +51.2% |
| Q4 FY2021 | Dec 31, 2021 | $233.14M | +179.7% |
| Q3 FY2021 | Sep 30, 2021 | $247.22M | +179.9% |
| Q2 FY2021 | Jun 30, 2021 | $256.43M | +258.0% |
| Q1 FY2021 | Mar 31, 2021 | $147.31M | +133.7% |
| Q4 FY2020 | Dec 31, 2020 | $83.35M | +10.4% |
| Q3 FY2020 | Sep 30, 2020 | $88.32M | +14.1% |
| Q2 FY2020 | Jun 30, 2020 | $71.63M | -3.0% |
| Q1 FY2020 | Mar 31, 2020 | $63.03M | -28.5% |
| Q4 FY2019 | Dec 31, 2019 | $75.52M | -20.6% |
| Q3 FY2019 | Sep 30, 2019 | $77.44M | +108.6% |
| Q2 FY2019 | Jun 30, 2019 | $73.84M | +70.6% |
| Q1 FY2019 | Mar 31, 2019 | $88.13M | +99.5% |
| Q4 FY2018 | Dec 31, 2018 | $95.09M | +93.2% |
| Q3 FY2018 | Sep 30, 2018 | $37.13M | +40.3% |
| Q2 FY2018 | Jun 30, 2018 | $43.29M | +37.3% |
| Q4 FY2017 | Dec 31, 2017 | $44.17M | +75.4% |
| Q3 FY2017 | Sep 30, 2017 | $49.23M | +68.6% |
| Q2 FY2017 | Jun 30, 2017 | $26.47M | -19.5% |
| Q1 FY2017 | Mar 31, 2017 | $31.53M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.19M | – |
| Q3 FY2016 | Sep 30, 2016 | $29.19M | – |
| Q2 FY2016 | Jun 30, 2016 | $32.88M | – |
See a number that looks wrong?